2nd mRNA Analytical Development Summit

Welcome to the 2nd mRNA Analytical Development Summit: Trailblazing Advanced Analytics for Superior mRNA Therapeutics and Vaccines

Uniting 80+ Senior Scientists, Directors, and Heads of Analytical Development, Quality Control, CMC and Regulatory - join us in Boston alongside pioneering speakers from innovative biopharma and KOLs of academia.

Avoid missing out on networking with those shaping the landscape of novel and emerging analytical tools and technologies for mRNA-based therapeutics and vaccines. Meet your community face-to-face in 2023 to hear how they address the major challenges facing the industry:

Explore Emerging Technologies and Novel Analytical Approaches for mRNA Therapeutics and Vaccines
With mRNA therapeutics and vaccines disrupting the industry, hear from the likes of Beam Therapeutics, Merck, and Pfizer on where innovation is expected to come from and discuss the opportunities emerging analytical and biological technologies offer over traditional methods

Improve Chemical-Based Assays and Nanoformulation for RNA-based Vaccines and Therapeutics
This meeting will shine the spotlight on novel analytical techniques for RNA-based therapeutics and vaccines and emerge into innovating nanoformulation as well as unravel the interaction between the drug product and cell with research institutes and companies including GSK, MIT, and CureVac

Understand Regulatory Expectations and Establish Clinical Success with Emerging Assays and Analytical Tools
Explore the FDA's personal perspective of common mistakes observed in regulatory submissions for analytical method validation and real-world examples of physicochemical methods previously submitted for biological drug testing

Overcome Scale-Up Challenges and Emerge into Bioanalytical Immunology
Discuss how to overcome analytical and scale-up challenges of emerging RNA modalities and how to find the balance between high immunoreactivity and low toxicity with insights from Ziphius Vaccines, BioNTech, and Replicate Bioscience

Delve into Advancements in Innovative Characterization Tools for mRNA-Based Therapeutics and Vaccines
Delve into pioneering approaches to characterize and purify RNA in lipid nanoparticles intended for base editing with Beam Therapeutics, Arcturus Therapeutics, and Seqirus

Join us February 14-16, 202 in Boston, MA!

URLs:
Brochure: https://go.evvnt.com/1317979-0?pid=10018
Website: https://go.evvnt.com/1317979-1?pid=10018
Tickets: https://go.evvnt.com/1317979-2?pid=10018

Prices:
Drug Developer - Conference + 2 Workshop: USD 5196.00,
Drug Developer - Conference + 1 Workshop: USD 4148.00,
Drug Developer - Conference Only: USD 3099.00,
Solution Provider - Conference + 2 Workshop: USD 5846.00,
Solution Provider - Conference + 1 Workshop: USD 4723.00,
Solution Provider - Conference Only: USD 3599.00,
Academic and Not for Profit - Conference + 2 Workshop: USD 4496.00,
Academic and Not for Profit - Conference + 1 Workshop: USD 3598.00,
Academic and Not for Profit - Conference Only: USD 2699.00

Speakers: Andrew Geall Co-Founder and Chief Development Officer Replicate Bioscience, Curtis Dobrowolski Co-Founder Nava Therapeutics, Daniel Anderson Professor MIT, Derek O'Hagan Senior Advisor R and D GSK, Emnet Yitbarek Scientist FDA, Felipe Gazos Lopez Associate Director Tessera Therapeutics, Heinrich Haas VP - Formulation and Drug Delivery BioNTech, Iulia Oita CMC Manager Ziphius Vaccines, Kalina Paunovska Co-Founder Nava Therapeutics, Lawrence Thompson Senior Principal Scientist Pfizer, Leonie Wyffels R and D Director Ziphius Vaccines, Li Li Principal Scientist Merck, Mohammad Safari Head of Analytical Biochemistry Seqirus, Poulami Talukder Senior Scientist Tiba Biotech, Siddharth Bhoraskar Scientist II, Analytical Sciences Beam Therapeutics, Stefan Heinz Director - Analytical Development CureVac, Theresa Goletz Global Head, Analytical Immunology and Cellular Platform GSK, Yu He Director - Analytical Research and Development Merck, Yurong Guo Director - Analytical Development ADQC Arcturus Therapeutics